Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
The Role of the Polyomavirus, JC Virus, in the Pathogenesis
of Colorectal CancerII Falk Gastro-Conference
Dresden, GermanyOctober 12, 2007
C. Richard Boland, M.D.Baylor University Medical Center
Dallas, Texas
Normal
5q (APC)alterations*
Adenoma
Colonic epithelium
Benignneoplasia
Advancedadenoma
Ras mutation
17p (p53)alterations*
Carcinoma
Malignantneoplasia
Larger
Fearon and Vogelstein, 1990
(* “alterations” imply both mutations and allelic losses, or CIN)
18q loss
Multistep Colorectal Carcinogenesis (1990)
Multiple Pathways to CRC (2007)
CIN TSG’s lost by LOH: APC, p53, 18q genes
LynchSyndrome
CIMP
MSILose DNA MMR gene
methylate hMLH1
Mutations at target genes:R2, Bax, etc.
TSG’s lost by methylation:APC, PTEN, HIC-1, p16, MGMT, etc. Cancer
Hypothesis (1994)
• Polyomaviruses encode a transforming gene (T-antigen)
• When cells are transformed (in the laboratory) with SV40 (a polyomavirus), they develop CIN and become aneuploid
• Perhaps a polyomavirus is in CRCs
Are Viruses Involved in the Pathogenesis of Any Cancers?
• Rous sarcoma virus (chickens)• Avian leukosis virus, etc (retroviruses)• Murine leukemia viruses, etc.• Oncogenes in NIH 3T3 cells (Bishop and
Varmus)• SV40 caused cancers in rodents (1960’s)
Are viruses involved in any human cancers?
• HPV and genital tract cancers – (possibly esophagus, nasopharyngeal, and other cancers)
• EBV and lymphomas (also gastric cancer?)• Kaposi’s sarcoma and herpes virus (HHV8)• HTLV-1 and lymphomas• Hepatitis B & C and hepatocellular carcinoma• Polyomaviruses
– SV40 and mesothelioma or lymphomas– JCV and CNS tumors
Polyomaviruses
• All encode a potent oncogene (T antigen)• All potentially potent oncogenic viruses
– Polyomavirus (mouse)– SV40 (monkeys)– JCV (human)– BKV (human)
Polyomavirus Structure
JC Virus (Mad1, complete genome)
5 kbp DNA virusClosed circular genomeSupercoiledEncodes 5 genes
T Antigen3 viral capsids
VP1, VP2, VP3Agnoprotein
Why JCV?
• Nearly all humans have antibody titers to JCV– every population studied (including Yanomami)– remains latent in most of us
• causes PML in immunosuppressed patients
• JCV has encodes a potent oncogene– T antigen
• JCV causes tumors when injected into the CNS of rodents or monkeys
• JCV is associated with “rogue” (aneuploid) lymphocytes in humans (James Neel)
T-Antigen Has Multiple FunctionalDomains
J.S. Butel, Baylor College of Medicine
Takes out the RB protein
Takes out p53
JCV DNA in Colorectal Tissues
Initial PCRn = 46 samples12/46 positive (26%)
With topoisomerase (TISPA)n = 54 samples48/54 positive (89%)
JCV in CRC: Confirmatory Studies
• *Laghi et al. PNAS, 1999 (89% CRCs)• *Ricciardiello et al., Gastro, 2000 (81%, nl colon)• *Ricciardiello et al., J. Virology, 2001
(promoters)• Enam et al., Cancer Res, 2002 (83%)• Theodoropoulis et al. Dis Col Rectum, 2005
(quantitated copy number)• Hori et al., Virchows Arch, 2005 (viral proteins)• Weinreb, Virchows Arch, 2006• *Jung et al, Cancer, 2007 (adenomatous polyps)
How Many Copies of JCV in Human Colorectal Neoplasms?
100-250147 (+50)6Normal
9-20 X 10314.0 (+3.1) x 103
15Adenomas
50-450242 (+127)35Adjacent normal
9-20 X 10314.3 (+4.2) X103
49Cancer
RANGEMEAN (SD)NTISSUE
Thoedoropoulos et al, Dis Colon & Rectum 2005
JCV in the GI Tract (I)Upper GI Tract (71%)
• esophagus: 10/15 (67%)• gastric corpus: 9/17 (53%)• gastric antrum: 8/17 (47%)• duodenum: 10/17 (59%)
Lower GI Tract (81%)• cecum: 10/15 (67%)• transverse colon: 11/16 (69%)• sigmoid colon: 8/16 (50%)• rectum: 10/16 (63%)
Interpretation
The GI tract is a reservoir for JCV
Suggests fecal-oral transmissionof the virus
Ricciardiello L at al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 119:1228-
1235, 2000.
JCV and other GI Cancers
• JCV is also present in cancers of the:
– Esophagus (DelValle et al. Cancer, 2005)– Stomach (Shin et al. Cancer, 2006)– Pancreas (Fuerst et al. Gastro, 2005 (abstr.)– Lung (Zheng et al. J Pathol, 2007)
MODEL 1: JCV T Ag in HCT116 cells
• HCT116 cells– diploid, MSI, no CIN– does not support JCV infection
• T Ag/GFP construct inserted into plasmid
• Plasmid transfected into HCT116
JCV T Ag in HCT116 Cells
• JCV T Ag protein localizes in the nucleus
• Transfected cells develop CIN
• Control constructs (GFP only): – no CIN
JCV TJCV T--Antigen Transfection Causes Antigen Transfection Causes CIN in HCT116 CellsCIN in HCT116 Cells
Dicentrics: A, C, F, G
Breaks: A, B, E
Fused: D, F, I
Rings: H
A B C
D E F
G H I
CIN IN HCT116/T Ag: CIN IN HCT116/T Ag: 90 Population Doublings90 Population Doublings
Clones ChromÕs Breaks Dicentric Rings Others
C1 409 0 0 0 0
C2 401 2 1 0 0
C3 457 1 0 0 FUSION
T Ag-1 332 10 11 17 0
T Ag-2 398 14 7 17 TRICEN-TRIC (2)
T Ag-3 402 17 3 3 FUSION
Model 2:Induction of CIN in RKO cells
A full JCV genome induces CIN in the diploid colon cell line:
RKO
Ricciardiello et al. Cancer Res 63:7256-62, 2003
Transfection of JCV Genome into Diploid CRC cells
• Model: RKO cells– diploid, microsatellite instability (MSI)
• hypermethylated hMLH1– wild type p53, APC, β-catenin– a CIMP model
• JCV cloned into pBR322 plasmid– full length, Mad-1 inserted into plasmid– transfected into RKO
Results: RKO transfected with JCV
• JCV integrates into RKO• T antigen expressed within 7 days
– nuclear localization of T Ag protein• VP1 expressed (late gene; viral capsid)
– low level expression• suggests viral replication
• T Ag and β-catenin interaction• p53 stabilized• CIN induced
Ricciardiello et al, Cancer Res 63:7256-62, 2003
JCV INDUCES CIN
Model 3:Making NMC460 cells tumorigenic
Normal Colonic Cells:NCM460 cells
• Normal, non-transformed colonic epithelial cell lines
• Derived from the normal colon mucosa of a 68-year-old Hispanic male and selected for in vitro growth.
• Cells were not infected or transfected with any exogenous genetic information.
• Expression of colonic epithelial cell-associated antigens, such as cytokeratins and villin.
• Normal colonic physiology (Gastroenterol.1997, Am J Physiol. 1998; 2000, JBC 1997, J Clin Invest 1997)
• Wild type p53 (Cancer Gene Therapy. 2000, Gastroenterol. 2005).
T antigen expression vector:CMV-JCV TAg
5019 of JCVRemoved TAg intronnt 4772/4426
nt 2473of JCV
20 bp AvaII-EcoRIadapter sequence
XbaI site of pVL1392 and pCR3
pCR3 pCR3
Authentic TAg polyA site
ATG5013
TAA2603
m 4274
Stable Transfected NCM460 with T-Ag
T-Ag
p53
- + + T-Ag Transfection
Clon
e_1_
8 wk
sCl
one_
2_8
wks
JCV T-Ag results in tumor formation in nude mice at 3 weeks
JCV Transformed NMC460 Cells in Nude Mouse
(No tumors from cells transfected with control vector)
JCV T Ag and β-Catenin• JCV DNA found in 83% of CRCs
– 22/27 tumors
• T Ag and agnoprotein expressed by IHC in >50% of CRCs (not viral capsid proteins)– β-catenin expression in nucleus of T Ag+ cells– T Ag not expressed in the normal colon
• T Ag and β-catenin co-immunoprecipitated
Enam et al Cancer Res 62:7093, 2002 (Khalili lab)
β-catenin regulates proliferation
nucleus
Tcf-4
β-catTarget genes
β-cat
Wnt-1
Frizzled(Receptor)
Cell membrane
APC
GSK3β
DSH
axin
C-myc, PPARδ, cyclin D, etcExpressed (proliferation program)
β-cat
β-cat
Wnt binds receptor
β-cat
APC inhibited
increasedβ-catenin
Proliferating cells:-nuclear β-catenin-no APC
APC regulates β-catenin
nucleus
Tcf-4 Target genes
cell-cell adhesion inhibitedWnt-1
Frizzled(Receptor)
Cell membrane
β-catAPC
GSK3β
DSH
β-cat
degradedaxin
genes repressed
α-cat
no ligand bound
x
x
Differentiated cells- APC expressed
- β-catenin degraded
0102030405060708090
100
Normal (150) Cancer (100) Adenoma (80) Ad/Ca withLOH of APC
(30)
APC +
beta-catnuc
APC and β-catenin IHC in Normal, Sporadic/FAP Adenomas and Cancers
Nuclear stabilization of β-catenin precedes loss of APC
Normal
5q (APC)alterations*
Adenoma
Colonic epithelium
Benignneoplasia
Advancedadenoma
Ras mutation
17p (p53)alterations*
Carcinoma
Malignantneoplasia
Larger
Fearon and Vogelstein, 1990
(* “alterations” imply both mutations and allelic losses, or CIN)
18q loss
Multistep Colorectal Carcinogenesis
β-catenin chaperoned to the nucleus by
JCV T-Ag
JCV T antigen expression may “chaperone” β-catenin, and initiate the neoplastic phenotype
JCV and Genomic/EpigeneticInstability in CRC
• JCV T Antigen expression occurs in about half of all CRCs with JCV DNA– CIN and CIMP inversely associated with each
other• CRCs develop as a consequence of JCV
– some permit expression of JCV genes, and develop CIN (most tumors)
– some respond to JCV with promoter methylation (CIMP)
Goel et al, Gastroenterology, 2007
CIMP: Summary of Results
• Expression of JCV T antigen in CRC cell lines induces promoter methylation and CIMP (in vitro)
Goel, unpublished data
SUMMARY
• Most people are infected with JCV• JCV is present in most GI cancers
– CRC, gastric, esophageal, pancreatic• T Ag can initiate a neoplastic phenotype
prior to any mutations via β-catenin • T Ag can induce CIN• JCV transfection can cause CIN• T Ag expression may induce CIMP
Conclusions (2007)• JCV is a plausible explanation for:
– CIN– CIMP– MSI (which is caused by either CIMP or CIN)
• This is the best available explanation for how GI cancers begin in humans
• This raises the hypothesis that if one could prevent infection, one might greatly reduce the incidence of GI cancers
Luigi Laghi, MDMilan, Italy
Initially optimizedJCV PCR, quant-itative JCV assays,etc.
KEY RESEARCH COLLABORATORS
Luigi Ricciardiello, MDAjay Goel, PhD
Found JCV throughout gutInduced CIN in RKO cellsRearrangements in promoter
KEY RESEARCH COLLABORATORS
Luigi Ricciardiello, MDAjay Goel, PhD
Association between JCV and CINAssociation between JCV and CIMPJCV in gastric cancerJCV in polypsMechanisms of genetic/epigenetic instability